These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32944474)
1. Acute Myasthenia Crisis: A Critical Emergency Department Differential. Hogan C; Lee J; Sleigh BC; Banerjee PR; Ganti L Cureus; 2020 Aug; 12(8):e9760. PubMed ID: 32944474 [TBL] [Abstract][Full Text] [Related]
2. Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders. Ohno K; Ohkawara B; Ito M Expert Opin Ther Targets; 2017 Oct; 21(10):949-958. PubMed ID: 28825343 [TBL] [Abstract][Full Text] [Related]
3. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability. Takamori M Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic and clinical classification of autoimmune myasthenia gravis. Berrih-Aknin S; Frenkian-Cuvelier M; Eymard B J Autoimmun; 2014; 48-49():143-8. PubMed ID: 24530233 [TBL] [Abstract][Full Text] [Related]
5. Delayed Diagnosis of Atypical Presentation of Myasthenia Gravis. Mustafa MS; Marshal M; Ahern E; Crowley P Eur J Case Rep Intern Med; 2018; 5(2):000785. PubMed ID: 30756011 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. Phillips WD; Vincent A F1000Res; 2016; 5():. PubMed ID: 27408701 [TBL] [Abstract][Full Text] [Related]
7. Roles of collagen Q in MuSK antibody-positive myasthenia gravis. Ohno K; Otsuka K; Ito M Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269 [TBL] [Abstract][Full Text] [Related]
9. Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. Yan M; Xing GL; Xiong WC; Mei L Ann N Y Acad Sci; 2018 Feb; 1413(1):126-135. PubMed ID: 29377176 [TBL] [Abstract][Full Text] [Related]
10. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266 [TBL] [Abstract][Full Text] [Related]
11. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451 [TBL] [Abstract][Full Text] [Related]
12. [Autoantibodies in myasthenia gravis]. Motomura M; Narita Masuda T Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991 [TBL] [Abstract][Full Text] [Related]
14. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Vincent A; Leite MI Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434 [TBL] [Abstract][Full Text] [Related]
15. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis. Li Z; Li M; Wood K; Hettwer S; Muley SA; Shi FD; Liu Q; Ladha SS Muscle Nerve; 2018 May; 57(5):814-820. PubMed ID: 29193204 [TBL] [Abstract][Full Text] [Related]